Search clinical trials for: Fesoterodine ER (fasted)

Total 11741 results

Pfizer

Completed

Study to Estimate the Relative Bioavailability Compared to Commercial Extended-release Tablet Formulation and the Effects of Food Or Sprinkling on Applesauce for Fesoterodine Sustained-release Beads-in-capsule Formulations in Healthy Adult Volunteers

Healthy

Belgium
Pfizer

Completed

BIOEQUIVALENCE STUDY IN HEALTHY PARTICIPANTS COMPARING 4 MG AND 8 MG FESOTERODINE EXTENDED-RELEASE TABLETS (TOVIAZ™), MANUFACTURED AT ZWICKAU VERSUS FREIBURG

Neurogenic Detrusor Overactivity

Belgium
Pfizer

Completed

Study To Assess The Bioequivalence Under Fed And Fasted Conditions Of The Fesoterodine Beads-In-Capsule SR4 And SR7 Formulations And To Estimate The Bioavailability of SR7 Beads Sprinkled On Apple Sauce Relative To The Beads-In-Capsule SR7 Formulation Administer

Neurogenic Detrusor Overactivity

Belgium
Pfizer

Completed

Open-label Long-term Extension Study of Fesoterodine in Japanese Subjects With Neurogenic Detrusor Overactivity.

Urinary Bladder, Neurogenic

Japan
Pfizer

Completed

A Study To Find Out How Fesoterodine Works In Children Aged 6 To 17 Years With Bladder Overactivity Caused By A Neurological Condition

Urinary Bladder, Neurogenic

France, United States, Spain, Korea, Republic of, United Kingdom, Malaysia, Taiwan, Finland, Japan, Lithuania, Italy, Turkey, Estonia, Slovakia, Belgium, Canada, Germany, Greece, India, Philippines, Poland, Russian Federation, South... and more
Pfizer

Completed

Clinical Trial to Evaluate the Efficacy and Safety of Fesoterodine in Comparison to Tolterodine Extended Release(ER)in Patients With Overactive Bladder.

Overactive Bladder

Canada, United States, Costa Rica, Hungary, Slovakia, Spain, Colombia, India, Russian Federation, Ireland, Korea, Republic of, Germany, Sweden, Poland, Bulgaria, Estonia, Brazil, Greece, Latvia, Lithuania, Malaysia, Romania, Singapore, South Africa and more
Pfizer

Completed

A 12 Week Study to Confirm the Effectiveness of 8mg of Fesoterodine Compared to 4mg of Fesoterodine

Overactive Bladder

Korea, Republic of, United States, Denmark, Germany, Canada, Hungary, Poland, France, United Kingdom, Slovakia, Sweden, Mexico, Czech Republic, Finland, Italy, Lithuania, Argentina, Chile, Colombia, Egypt, Greece, Norway, Philippines, Russian Federation and more
AstraZeneca

Withdrawn

A Study to Compare the Pharmacokinetics of Different Formulations of AZD9977 and the Influence of Food in Healthy Male Subjects

Healthy Male Subjects | Pharmacokinetics | Safety | Food Effect

United Kingdom
Pfizer

Completed

A Clinical Trial To Assess Fesoterodine On Treatment Satisfaction And Symptom Improvement In Overactive Bladder Patients

Overactive Bladder

Costa Rica, United States, Korea, Republic of, Germany, Slovakia, Ukraine, Belgium, Poland, Czechia
Pfizer

Terminated

Non-Interventional Study To Investigate Whether Information Provided To Patients Influences Their Satisfaction With Toviaz Therapy

Urinary Bladder, Overactive
Pfizer

Completed

A Study to Compare the Effectiveness and Safety of Fesoterodine and Placebo in an Elderly Population of Patients Who go to the Toilet Very Frequently Due to Overactive Bladder. (SOFIA)

Urinary Bladder, Overactive

Portugal, Spain, Turkey, Finland, Germany, Norway, Sweden, Slovakia, Italy, Austria, United Kingdom, Belgium, Denmark, Israel, Switzerland
Rigshospitalet, Denmark
The Novo Nordic Foundation

Recruiting

Pre-habilitation Interventions to Empower Patients With Chronic Pain

Chronic Non-Cancer Pain

Denmark
Pfizer

Completed

Drug Use Investigation for Toviaz

Overactive Bladder (OAB)
Pfizer

Completed

Study In Patients With Overactive Bladder Treated With Toviaz® After Failure Of Previous Therapy

Overactive Bladder | Urinary Incontinence

Slovakia
Pfizer

Completed

A Clinical Study in Patients With Overactive Bladder With Leakage of Urine, to Find Out if the Medicine, Fesoterodine, Works in Those Patients Who Did Not Have Enough Response to the Medicine, Tolterodine.

Urinary Bladder, Overactive

Canada, United States, Germany, Russian Federation, Czechia, Egypt, Bulgaria, Finland, Hungary, Korea, Republic of, Mexico, Poland, South Africa, Sweden, Ukraine
Pfizer

Completed

A Study To Estimate The Effects Of Food On Drug Fesoterodine Fumarate And The Pharmacokinetics Of 5-Hydroxymethyl Tolterodine (5-HMT) In Healthy Volunteers

Urinary Bladder, Overactive

Singapore
Washington University School of Medicine

Completed

Comparative Urine Proteomic Studies of Overactive Bladder in Humans

Overactive Bladder

United States
Pfizer

Completed

Long Term Study To Evaluate the Safety, Tolerability and Efficacy of Fesoterodine for Overactive Bladder.

Overactive Bladder

Japan
Mayo Clinic

Terminated

Trial of Percutaneous Tibial Nerve Stimulation (PTNS) Versus PTNS and Fesoterodine Fumarate

Overactive Bladder

United States
University of North Carolina, Chapel Hill
National Institute on Aging (NIA)

Completed

Understanding the Response to Fesoterodine Through Genetic Evaluation in the Elderly (URGE) (URGE)

Urge Urinary Incontinence

United States
Pfizer

Completed

Dose-Finding Study To Evaluate The Efficacy, Tolerability And Safety Of Fesoterodine In Comparison To Placebo For Overactive Bladder.

Overactive Bladder

Korea, Republic of, Taiwan, Hong Kong, Japan
Weill Medical College of Cornell University
Pfizer

Completed

An Open Label Study to Measure Efficacy of Fesoterodine (Toviaz) Post Surgery for Benign Prostatic Hyperplasia (Toviaz)

Bladder Outlet Obstruction

United States
Pfizer

Completed

The Effect Of Fesoterodine On Pharmacokinetics And Pharmacodynamics Of Warfarin In Healthy Subjects

Urinary Bladder, Overactive

United States
Pfizer

Terminated

Multiple Dose Study To Investigate The Effects Of Fesoterodine And Solifenacin On Gastrointestinal Transit

Healthy

United States
Saint Thomas Health
Pfizer

Withdrawn

Neuropathic Investigation and Anticholinergic Treatment of Bladder Dysfunction in Diabetes and Stroke Patients

Urinary Incontinence | Bladder Dysfunction

United States
Pfizer

Completed

This Is A Study Of Bioavailability And Food Effect For Fesoterodine.

Overactive Bladder (OAB) With Symptoms of Frequency, Urgency, and Urgency

United States
RVL Pharmaceuticals, Inc.
Osmotica Pharmaceutical US LLC

Withdrawn

To Assess Effects of Arbaclofen ER Tablets Compared With Placebo on Sperm Parameters in Male Subjects With MS

Multiple Sclerosis | Sperm

United States
Zogenix, Inc.

Completed

To Assess the Rate and Extent of Absorption of Hydrocodone From 20 mg Hydrocodone Bitartrate Extended-Release Capsules

Healthy
Boehringer Ingelheim

Completed

Relative Bioavailability of Different Oral Viramune Extended Release Formulations Compared to Viramune® Oral Suspension in Healthy Male Volunteers

Healthy
Rhode Island Hospital

Completed

Improving Emotion Regulation Skills Among Adolescents Attempting to Lose Weight

Overweight and Obesity

United States
University of Alberta
Pfizer

Completed

A Study of Fesoterodine and Oxybutynin on Cognitive Function in Mild Cognitive Impairment

Overactive Bladder | Mild Cognitive Impairment

Canada
Columbia University
Biolase Inc

Active, not recruiting

Peri-implantitis Treatment: Clinical Results of Conventional Treatment vs. the Addition of Biolase

Peri-Implantitis

United States
HealthPartners Institute

Terminated

Outreach-ER: A Dementia Care Intervention Program

Dementia

United States
Uppsala University

Recruiting

Emotion Regulation Training for Adolescents With ADHD

ADHD | Emotion Regulation | Attention Deficit Disorder With Hyperactivity

Sweden
Jewish General Hospital

Recruiting

Emergency Room Visits and Older Patients (ER2) (ER2)

Emergencies | Length of Stay

Canada
Medical University of South Carolina
Georgia State University

Completed

PTSD Treatment and Emotion Regulation Skills Training for Veterans With Military Sexual Trauma (PE+ER) (PE+ER)

Anxiety Disorders | Stress Disorders, Post-Traumatic | Mental Disorder | Traumatic Stress Disorder

United States
TaiRx, Inc.

Completed

Safety and Pharmacokinetic Study of CVM-1118 Extended-Release in Advanced Cancer Patients

Advanced Cancer

Taiwan
Asieris Pharmaceuticals (AUS) Pty Ltd.

Completed

A Phase I, Two-phase, Crossover Study to Evaluate the Safety, Tolerability and Pharmacokinetics of APL-1501 ER Tablets

Bladder Cancer

Australia
Member Companies of the Opioid PMR Consortium

Terminated

Discontinuation vs Continuation of Long-term Opioid Therapy in Suboptimal and Optimal Responders With Chronic Pain

Opioid-Related Disorders | Drug Abuse | Opiate Addiction | Narcotic Abuse

United States
Washington State University
American Society for Pain Management Nursing

Recruiting

Empowered Relief Delivered by Nurses (ERA)

Pain, Chronic

United States
National Institute of Mental Health (NIMH)

Completed

Assessment of [11C]ER176 to Image Translocator Protein in Brain and Whole Body of Healthy People

Pharmacokinetics | Adult

United States
Korea University Anam Hospital

Completed

YSGG Application in Periodontal Treatment

Periodontal Diseases

Korea, Republic of
Lotus Pharmaceutical

Completed

Evaluation of the Efficacy and Safety of Laxymig® as Prophylactic Treatment in Patients With Migraine

Migraine Without Aura | Migraine With Aura

Taiwan
Kowa Research Institute, Inc.

Completed

Study to Investigate the Efficacy and Pharmacokinetic Profile of K-877-ER Compared to K-877-IR

Dyslipidemia

United States
Pfizer

Completed

Clinical Trial to Evaluate the Efficacy and Safety of Fesoterodine in Comparison to Tolterodine for Overactive Bladder (OAB)

Overactive Bladder

Denmark, United States, Canada, Costa Rica, Belgium, Czech Republic, Colombia, Germany, Hungary, Korea, Republic of, Spain, Chile, Taiwan, India, Brazil, Singapore, Greece, Hong Kong, Italy, Sweden, Poland, South Africa, Malaysia, Rom... and more
Rambam Health Care Campus

Unknown

Solifenacin Succinate Versus Fesoterodine A Comparison Trial for Urgency Symptoms

Urinary Bladder, Overactive

Israel
Ultragenyx Pharmaceutical Inc

Completed

Safety and Pharmacokinetics of Sialic Acid Tables in Patients With Hereditary Inclusion Body Myopathy (HIBM)

Hereditary Inclusion Body Myopathy (HIBM)

United States
Boehringer Ingelheim

Completed

Bioavailability of Four Oral Prototype Extended Release Formulations With BI 11634 in Healthy Male Volunteers

Healthy
Lars Adolfsson

Recruiting

Non-operative Treatment in Sweden of Proximal Humeral Fractures (NOSWEPH)

Proximal Humeral Fracture

Sweden
University Hospital Inselspital, Berne

Completed

Feasibility of REBOA in Refractory Cardiac Arrest

Heart Arrest

Switzerland

3

Subscribe